琥珀酸索利那新治疗50例神经原性逼尿肌过度活动的疗效和安全性  

作　　者：钟伟湘[1] 高小川[1] 刘静[1] 黄杨[1] 骆广旗[1] 刘秋玲[1] 陈湜[1] 

机构地区：[1]广东省工伤康复中心,广东广州510440

出　　处：《中国药业》2012年第A02期16-16,共1页China Pharmaceuticals

摘　　要：目的探讨琥珀酸索利那新治疗脊髓损伤并发神经原性逼尿肌过度活动的疗效和安全性。方法50例患者．琥珀酸索利那新剂量为每次5mg，每日1次。结果入选患者50例，服药后1个月患者尿失禁由10．6次／天减少至6．3次／天；患者储尿期逼尿肌压力由47．76emH20降至29．34cmH2O；膀胱安全容量由173．46mL增加至246mL。患者服药后出现口干3例，头晕2例，便秘2例，总不良事件发生率14％。结论琥珀酸索利那新脊髓损伤并发神经原性逼尿肌过度活动疗效良好，且不良反应少。Objective To evaluate the effection and safety of solitenacin on neurogenic detrusor overactivity.Methods 50 spinal cord Injury patients with neurogenic detrusor overactivity was included.All were given 5 mg solifenacin every day.The data of urinary diary and urodynamics were observed.Results After 1 month,the urinary incontinence changed from 10.6 to 6.3 everyday, the detrusor pressure in filling phase 47.76 cm H20 to 29.34 cm H2O,the bladder capactivity 173.46 mL up to 246 mL.The adverse drug reaction （14%）：dry mouth in 3 cases,headache in 2 cases,comstipafion in 2 cases.Conclusions Solifenacin is safe and effective for the treatment of neurogenic detrusor overactivity.

关 键 词：琥珀酸索利那新 神经原性逼尿肌过度活动 疗效安全性 

分 类 号：R746[医药卫生—神经病学与精神病学]